Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

mal responses was, as previously reported, 44% (18 out of 41 patients evaluable for response). Of the 18 responding patients (44%), 8 out of 14 patients were bortezomib-nave (57%); 7 out of 16 patients were bortezomib-pretreated patients (44%); and 3 out of 11 patients were bortezomib-refractory (27%). Responses in the bortezomib-refractory patients continue to show prolonged duration (at least 10 months at the time of data presentation at ASCO in June 2007) and meaningful reduction of serum/urinary M-protein (greater than 89%). The combination of tanespimycin and bortezomib was well-tolerated.

Kosan has been granted orphan drug designation for tanespimycin in multiple myeloma in both the US and European Union.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with R
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CORONA, Calif. and VIENNA, Va. ... an innovative in-home care provider that operates in ... with BeClose, a leading provider of remote caregiving technology. Alta ... new and existing client receiving homecare services. ... believe this technology is the key to providing the ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... to acquire 100% of QCR & Trio Diagnostics Limited, ... organization. The transaction closed on November 17, 2014. ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... DUBLIN, October 18, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... the PRECiSE 3 (P3) open label extension study for ... maintenance trial for an anti-TNF in Crohn,s disease, will ... the American College of Gastroenterology (ACG), taking place in ... efficacy data from the PRECiSE 4 (P4) clinical trial ...
Cached Medicine Technology:Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 2Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 3Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 4Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 5Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 6Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 7UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 2UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 3UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 4UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 5UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 6UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 7UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 8UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 9UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 10UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 11
(Date:11/22/2014)... A new AlignLife Chiropractic & Natural ... downtown Greenville area. Dr. Chelsea Sineath, owner and chiropractor ... open her own clinic after working in another AlignLife ... , AlignLife believes that the body can heal ... on chiropractic care and rehabilitation to allow the spine ...
(Date:11/22/2014)... PrettyTailor , an outstanding dress company, has recently ... can buy new dresses at its online shop now. ... , As a matter of fact, PrettyTailor specializes in ... four types of wedding outfits, including bridesmaid dresses, mother ... also provides a variety of occasion dresses, such as ...
(Date:11/22/2014)... A classic black prom dress will never go out ... has unveiled its new items of black prom gowns ... a big discount, up to 70% off. People throughout the ... black prom dresses, made with the best materials, can make ... all customers, the company provides these beautiful outfits in a ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 BambooFlooringChina.com ... the company has proudly released its new collection of ... discounted rates, up to 29% off. , According ... and sturdy tree-like grass, making it a highly renewable resource. ... products have a mixing color which comes from natural bamboo ...
(Date:11/22/2014)... York, NY (PRWEB) November 22, 2014 ... Therapeutics Goods Administration (TGA) approved it for use ... was approved and listed within the Therapeutic Goods ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione will ... a biotech specialist that sources and imports fine ...
Breaking Medicine News(10 mins):Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... 26 The AMERIGROUP Foundation,today announced that Senator ... its "Champion for Children" award., The award ... outstanding public advocacy efforts by government and community,leaders ... "Our goal is to work together with ...
... a company,developing breakthrough molecular imaging agents for ... it has entered into a licensing,agreement with ... and,commercialization of agents for diagnosis and treatment ... were co-developed by,FluoroPharma and MGH scientists, target ...
... plagues African populations , , WEDNESDAY, March 26 (HealthDay News) ... from the environment the organism that causes devastating and ... according to a new report. , The study ... idea that the organism, Mycobacterium ulcerans , is ...
... Partnership Develops First-Ever Toolkits to Address ,The ... in America Today, SACRAMENTO, Calif., March 26 ... activities, the California Association of,Health Plans (CAHP) and ... up to encourage physicians to discuss healthier,lifestyles with ...
... by the National Oncologic PET Registry (NOPR) showing that ... a molecular level, which then caused physicians to change ... has corroborated decades of nuclear medicine research. , These ... some time: molecular imaging is a powerful tool in ...
... Corporation will host,their second annual medical device ... in Bedford, Massachusetts., (Logo: http://www.newscom.com/cgi-bin/prnh/20071228/TOXIKONLOGO ... to be updated and revised,medical device manufacturers ... product. With new innovations and applications in,development, ...
Cached Medicine News:Health News:Texas Senator Kirk Watson Honored as 'Champion for Children' by the AMERIGROUP Foundation 2Health News:FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD) 2Health News:Scientists Isolate Organism That Causes Disfiguring Tropical Disease 2Health News:California Association of Health Plans & California Medical Association Foundation Team Up to Combat Obesity 2Health News:California Association of Health Plans & California Medical Association Foundation Team Up to Combat Obesity 3Health News:California Association of Health Plans & California Medical Association Foundation Team Up to Combat Obesity 4Health News:PET confirmed as valuable cancer diagnostic and disease-staging tool 2
Carbo-Seal Valsalva AAP is the first valved graft to replicate the natural Sinus of Valsalva, encouraging the natural formation of systolic vortices....
... for this technique is acquired tricuspid ... for tricuspid repair are based on ... diagnosed by angiography and dye dilution ... patients with an irreversible tricuspid insufficiency, ...
Current annuloplasty rings and bands are designed for symmetric dilatation. The IMR ETlogix ring is the first asymmetric ring designed to treat asymmetric dilatation....
PremierEdge™ Stab Knives - 45°....
Medicine Products: